Publication:
Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine

Issued Date

2019-12-01

Resource Type

Article

ISSN

20411723

DOI

10.1038/s41467-019-08854-2

Other identifier(s)

2-s2.0-85061820667

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

Nature Communications. Vol.10, No.1 (2019)

Suggested Citation

Slim Fourati, Susan Pereira Ribeiro, Filipa Blasco Tavares Pereira Lopes, Aarthi Talla, Francois Lefebvre, Mark Cameron, J. Kaewkungwal, P. Pitisuttithum, S. Nitayaphan, S. Rerks-Ngarm, Jerome H. Kim, Rasmi Thomas, Peter B. Gilbert, Georgia D. Tomaras, Richard A. Koup, Nelson L. Michael, M. Juliana McElrath, Raphael Gottardo, Rafick Pierre Sékaly Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine. Nature Communications. Vol.10, No.1 (2019). doi:10.1038/s41467-019-08854-2 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/50023

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine

Author(s)

Slim Fourati
 Susan Pereira Ribeiro
 Filipa Blasco Tavares Pereira Lopes
 Aarthi Talla
 Francois Lefebvre
 Mark Cameron
 J. Kaewkungwal
 P. Pitisuttithum
 S. Nitayaphan
 S. Rerks-Ngarm
 Jerome H. Kim
 Rasmi Thomas
 Peter B. Gilbert
 Georgia D. Tomaras
 Richard A. Koup
 Nelson L. Michael
 M. Juliana McElrath
 Raphael Gottardo
 Rafick Pierre Sékaly

Other Contributor(s)

International Vaccine Institute, Seoul
 Thailand Ministry of Public Health
 Walter Reed Army Institute of Research
 Mahidol University
 National Institutes of Health, Bethesda
 Royal Thai Army
 Duke University School of Medicine
 Fred Hutchinson Cancer Research Center
 Case Western Reserve University
 Canadian Center for Computational Genomics

Abstract

© 2019, The Author(s). The RV144 vaccine trial showed reduced risk of HIV-1 acquisition by 31.2%, although mechanisms that led to protection remain poorly understood. Here we identify transcriptional correlates for reduced HIV-1 acquisition after vaccination. We assess the transcriptomic profile of blood collected from 223 participants and 40 placebo recipients. Pathway-level analysis of HIV-1 negative vaccinees reveals that type I interferons that activate the IRF7 antiviral program and type II interferon-stimulated genes implicated in antigen-presentation are both associated with a reduced risk of HIV-1 acquisition. In contrast, genes upstream and downstream of NF-κB, mTORC1 and host genes required for viral infection are associated with an increased risk of HIV-1 acquisition among vaccinees and placebo recipients, defining a vaccine independent association with HIV-1 acquisition. Our transcriptomic analysis of RV144 trial samples identifies IRF7 as a mediator of protection and the activation of mTORC1 as a correlate of the risk of HIV-1 acquisition.

Keyword(s)

Biochemistry, Genetics and Molecular Biology
 Chemistry

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/50023

Collections

Scopus 2019